Injectable Formulation for Poorly Soluble Compound Using pH Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The compound 1-(5-(2,4-difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-1H-pyrrol-3-yl)-N-methylmethanamine has poor water solubility and stability, particularly in neutral pH environments, making it challenging to formulate for injection with adequate dissolution and stability.
Innovation Solution
A formulation comprising the compound, cyclodextrin, and an isotonizing agent, with a pH range of 4.0 to 6.0, is developed to enhance solubility and stability, using beta-cyclodextrin and sodium chloride as preferred components, to create a stable injectable pharmaceutical composition.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If the compound is formulated in a neutral pH environment, then water solubility is improved, but stability deteriorates due to acid decomposition
Solution Approach 1:
The patent applies parameter changes by adjusting the pH of the formulation to a specifically controlled acidic range (pH 3.0-5.0, preferably pH 3.5-4.5) rather than using a neutral pH environment. This pH optimization resolves the contradiction by finding the optimal balance point where the compound maintains adequate water solubility while minimizing acid decomposition, thereby achieving both solubility improvement and stability preservation simultaneously.
2Quantity of substance
If the compound is formulated in an acidic environment, then water solubility is improved, but stability deteriorates due to increased acid decomposition products
Solution Approach 1:
The patent applies parameter changes by precisely controlling the pH within a narrow acidic range (pH 3.0-5.0, preferably pH 3.5-4.5) rather than using strong acidic conditions. This optimized pH parameter allows the formulation to achieve good water solubility while minimizing acid decomposition products, thereby resolving the contradiction between solubility improvement and stability maintenance.
3Reliability
If the compound is formulated for injection, then therapeutic effectiveness is improved, but formulation difficulty increases due to poor solubility and stability
Solution Approach 1:
The patent applies parameter changes by optimizing the pH to a specifically controlled range (pH 3.0-5.0, preferably pH 3.5-4.5) and selecting appropriate excipients compatible with this pH range. This parameter optimization enables the compound to be formulated for injection by achieving both adequate solubility and stability, thereby resolving the contradiction between therapeutic effectiveness and formulation difficulty.
Solution Approach 2:
The patent employs intermediaries (excipients) that are compatible with the optimized pH range to facilitate the formulation process. These intermediaries help maintain the compound's stability and solubility in the injectable formulation, reducing formulation difficulty while preserving therapeutic effectiveness.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation achieves high solubility and stability, reducing the production of acid decomposition products and maintaining effectiveness for treating gastrointestinal ulcers and Helicobacter pylori-related issues, with improved storage and administration properties.
Implementation Method 1
a formulation for injection comprising: a compound represented by the following Chemical Formula 1 or a pharmaceutically acceptable salt thereof; a cyclodextrin; and an isotonizing agent
Implementation Method 2
a formulation for injection comprising: a compound represented by the following Chemical Formula 1 or a pharmaceutically acceptable salt thereof; a cyclodextrin; and an isotonizing agent
Data Source
AI summary
The present disclosure relates to a formulation for injection comprising 1-(5-(2,4-difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-1H-pyrrol-3-yl)-N-methylmethanamine.